article
Tweaking synonymous sites for gene therapy and vaccines
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
List view / Grid view
Covid-19
news
More COVID-19 research on mucosal immune system required, scientists say
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
news
SARS-CoV-2 mutations do not increase transmissibility, research shows
Having analysed the SARS-CoV-2 genomes from over 46,723 patients, researchers have found no mutations that increase transmissibility.
news
SARS-CoV-2 immune cells remain in body, providing rapid response to re-infection
A research team has shown that T-cell responses specific to SARS-CoV-2 remain in the body after infection, providing immunity from mild re-infection.
article
Neuropilin-1: a key receptor in SARS-CoV-2 infection
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
article
Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
COVID-19 is known to infect the lungs; however, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, Professor Lyle Armstrong and colleagues have been working to develop a human lung epithelium model of SARS-CoV-2 infection and replication. In this article, he describes…
article
Investigating cellular pathways driving severe COVID-19 with proteomics
Researchers from Massachusetts General Hospital have studied several thousand circulating proteins within the plasma proteome of symptomatic COVID-19 patients and acutely ill non-COVID-19 controls. Nikki Withers discussed their findings and implications of the study with one of the lead authors, Dr Mike Filbin.
article
COVID-19 In-Depth Focus 2020
This in-depth focus features articles on neuropilin-1, a potential new target for COVID-19 drug development, the creation of a lung model to enhance our understanding of SARS-CoV-2 infections and using proteomics to uncover the mechanisms behind COVID-19 symptom severity.
news
CD209 antigen could be a promising target for preventing severe COVID-19
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
news
Computational model used to predict drug targets against SARS-CoV-2
A model of a human lung cell has been used to understand how SARS-CoV-2 uses host cell processes to reproduce, revealing drug targets.
article
Drug Target Review – Issue 4 2020
In this journal, find articles discussing antimicrobial resistance, exploring why inhibiting the interaction between SARS-CoV-2 and neuropilin-1 could help combat COVID-19, as well as how CRISPR can be used to enhance productivity in cell line development. Also in this issue, features on engineering new biologic drugs and precision medicine.
news
Epidemiological data on SARS-CoV-2 uncovers insights into mutations
Researchers have analysed 750 samples from patients with SARS-CoV-2 to discover details about its transmission and mutational properties.
article
The latest pre-clinical HIV vaccine developments
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
news
3D view of SARS-CoV-2 replication cycle could enable antiviral drug development
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
news
Antibodies from previous COVID-19 infection protect patients for six months
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
